Construction and evaluation of a novel Stx2a-based immunotoxin against epidermal growth factor receptor (EGFR)
- 1 May 2025
- journal article
- Published by Elsevier in Biologicals
- Vol. 91, 101833
Abstract
No abstract availableKeywords
Funding Information
- Baqiyatallah University of Medical Sciences
- Islamic Azad University
This publication has 29 references indexed in Scilit:
- A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analysesEuropean Journal of Pharmacology, 2023
- Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivoClinical and Translational Oncology, 2021
- Breast cancer targeted/ therapeutic with double and triple fusion ImmunotoxinsThe Journal of Steroid Biochemistry and Molecular Biology, 2020
- Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancerCancer Letters, 2019
- Potential impact of invasive surgical procedures on primary tumor growth and metastasisClinical & Experimental Metastasis, 2018
- Emerging functions of the EGFR in cancerMolecular Oncology, 2017
- Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR)Protein Expression and Purification, 2016
- Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR)Protein Expression and Purification, 2016
- Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entitiesJournal of Cancer Research and Clinical Oncology, 2015
- Cancer Treatment with Gene Therapy and Radiation Therapy2012